Literature DB >> 6482087

Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.

T Aoyama, Y Ino, M Ozeki, M Oda, T Sato, Y Koshiyama, S Suzuki, M Fujita.   

Abstract

FUT-175, 6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulfonate (nafamstat mesilate), a novel synthetic protease-inhibiting agent, was studied to determine its in vitro effects against various proteases and other enzymes, as well as to determine its in vivo protease inhibitory effects. FUT-175 was found to inhibit, in an intense, specific and reversible way, the enzyme activities of trypsin, C1r, C1s, thrombin, kallikrein and plasmin with IC50 values of the order of 10(-6)-10(-8) M. FUT-175 also inhibited complement-mediated hemolysis, including both classical and alternative pathways, sites of inhibition being on C1r and C1s as evidenced by the intermediate-cell technique. In animal model reactions in which the complement system is known to be involved as pathogenetic factors, e.g., Forssman shock, Forssman cutaneous vasculitis, zymosan-induced paw edema, endotoxin shock and local Shwartzman reaction, FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock. FUT-175 was also found to be effective in trypsin-induced shock in mice, in lethality due to thrombin-thrombosis in mice and in kinin formation in the inflammatory process in rats.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6482087     DOI: 10.1254/jjp.35.203

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  45 in total

1.  The present status of casualty care in Japan and the role of anesthesiologists.

Authors:  T Fujita; T Imai
Journal:  J Anesth       Date:  1990-01       Impact factor: 2.078

2.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

3.  Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon.

Authors:  Koji Sawada; Akimitsu Egashira; Kunio Ohnishi; Ken Fukunaga; Takeshi Kusaka; Takashi Shimoyama
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

4.  Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease.

Authors:  K Sawada; K Ohnishi; S Fukui; K Yamada; M Yamamura; K Amano; K Amano; M Wada; N Tanida; M Satomi
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

5.  Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy.

Authors:  K Sawada; K Ohnishi; T Kosaka; S Chikano; A Egashira; M Okui; S Shintani; M Wada; K Nakasho; T Shimoyama
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

6.  Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yuki Fujiwara; Kenei Furukawa; Ryota Iwase; Tadashi Uwagawa; Takeyuki Misawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  Dig Dis Sci       Date:  2012-07-18       Impact factor: 3.199

7.  A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.

Authors:  Toshiaki Sendo; Yoshinori Itoh; Takeshi Goromaru; Tomoko Sumimura; Mami Saito; Keisei Aki; Takahisa Yano; Ryozo Oishi
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus.

Authors:  G Wild; J Watkins; A M Ward; P Hughes; A Hume; N R Rowell
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

9.  Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.

Authors:  S Ikehara; K Shimamura; T Aoyama; S Fujii; Y Hamashima
Journal:  Immunology       Date:  1985-08       Impact factor: 7.397

10.  Prevention of experimental acute pancreatitis by intraduodenal trypsin inhibitor in rat.

Authors:  H Ono; T Hayakawa; T Kondo; T Shibata; M Kitagawa; Y Sakai; S Kiriyama; H Sobajima
Journal:  Dig Dis Sci       Date:  1990-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.